Core Insights - The company reported a significant increase in product revenue for the first half of 2025, reaching 17.36 billion yuan, a year-on-year growth of 45.8% [1] - Total revenue for the same period was 17.52 billion yuan, reflecting a 46.0% increase compared to the previous year [1] - The net profit attributable to the parent company was 450 million yuan [1] Revenue Breakdown - The growth in product revenue was primarily driven by sales of self-developed products such as Baiyueze® (Zebutinib capsules) and licensed products from Amgen, as well as Baizean® (Tislelizumab injection) [2] - Baiyueze® achieved global sales of 12.53 billion yuan, marking a 56.2% year-on-year increase, with U.S. sales contributing 8.96 billion yuan, up 51.7% [2] - European sales of Baiyueze® totaled 1.92 billion yuan, a significant increase of 81.4%, while sales in China reached 1.19 billion yuan, growing by 36.5% [2] Product Performance - Baizean® recorded sales of 2.64 billion yuan, a 20.6% increase, driven by new indications approved for reimbursement in China [3] - Baiyueze® is noted for having the broadest range of approved indications among BTK inhibitors globally and is the only one with flexible dosing options [3] - The company has conducted over 35 clinical trials involving approximately 7,100 patients for Baiyueze®, which is now approved in 75 markets worldwide [3] R&D and Future Prospects - The company is advancing its next-generation self-developed pipeline products with a focus on rapid early clinical concept validation [4] - The global R&D team consists of over 3,700 personnel, collaborating with regulatory bodies and researchers across more than 45 countries [4] - The company anticipates over 20 milestone advancements in its hematological and solid tumor pipelines within the next 18 months [4]

【品大事】 仙鹤股份：拟110亿元投建林浆纸用一体化高性能纸基新材料项目 仙鹤股份公告，公司拟投资约110亿元建设林浆纸用一体化高性能纸基新材料项目，其中一期投资约55 亿元，二期投资约55亿元，正式动工之日起计三年内实现一期投产。一期项目计划投资约55亿元，预计 年产值约51.5亿元，年税收约4.5亿元，提供就业岗位约2000人。二期项目将根据一期项目的实施情况， 参照市场形势和企业经营情况，适时投资建设。 8月6日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者参 考。 中信证券公告，公司控股子公司华夏基金2025年上半年实现营业收入42.58亿元，净利润11.23亿元，综 合收益总额11.06亿元。截至2025年6月30日，华夏基金母公司管理资产规模为28512.37亿元。上述数据 为初步核算数据，未经会计师事务所审计，具体数据以公司2025年半年度报告中披露的数据为准。 百济神州：上半年净利润4.5亿元 同比扭亏为盈 百济神州公告，2025年半年度公司产品收入为173.60亿元，较上年同比上升45.8%；营业总收入175.18 亿元，较上年同比上升46.0%；归属于母公 ...

Financial Performance - In the first half of 2025, the company's product revenue reached 17.36 billion yuan, a year-on-year increase of 45.8% [1] - Total operating revenue for the same period was 17.52 billion yuan, reflecting a 46.0% year-on-year growth [1] - The net profit attributable to the parent company was 450 million yuan [1] - As of the end of the reporting period, total assets amounted to 44.87 billion yuan, an increase of 4.8% from the beginning of the period [1] - Equity attributable to the parent company was 26.86 billion yuan, up 11.1% from the beginning of the period [1] Product Sales - Global sales of Baiyueze® (Zebutinib Capsules) totaled 12.53 billion yuan, marking a 56.2% year-on-year increase, solidifying its leadership in the hematologic oncology field [2] - Sales in the United States reached 8.96 billion yuan, a 51.7% increase, driven by strong demand across all indications and favorable net pricing [2] - European sales amounted to 1.92 billion yuan, up 81.4%, attributed to market share gains in major European markets including Germany, Italy, Spain, France, and the UK [2] - In China, sales were 1.19 billion yuan, a 36.5% increase, due to growth in approved indications [2] - Baizean® (Trelatuzumab Injection) generated sales of 2.64 billion yuan, reflecting a 20.6% year-on-year growth, driven by new indications included in medical insurance and increased hospital supply [2] - Baizean® maintains a leading market share in China's PD-1 market [2]

Core Viewpoint - The company expects its revenue for 2025 to be between 35.8 billion and 38.1 billion yuan, with a significant increase attributed to its leading position in the U.S. market and ongoing expansion in Europe and other key global markets [1] Revenue and Expenses - The projected revenue growth is primarily driven by the strong market presence of Baiyueze in the U.S. and its continuous expansion in Europe and other important global markets [1] - Research and development expenses, along with sales and management expenses, are expected to total between 29.5 billion and 31.9 billion yuan [1] Profitability - The gross margin is anticipated to be in the mid-to-high range of 80% to 90%, with improvements attributed to better product mix and increased production efficiency [1]

Core Insights - The company reported a significant increase in product revenue and total revenue for the first half of 2025, with product revenue reaching 17.36 billion yuan, a year-on-year increase of 45.8%, and total revenue at 17.52 billion yuan, up 46.0% from the previous year [1] Financial Performance - For the first half of 2025, the net profit attributable to the parent company was 450 million yuan [1] - Total assets at the end of the reporting period amounted to 44.87 billion yuan, reflecting a 4.8% increase from the beginning of the period [1] - Equity attributable to the parent company increased by 11.1% to 26.86 billion yuan [1] Product Sales Performance - The global sales of Baiyueze (Zebutinib capsules) totaled 12.53 billion yuan, marking a 56.2% year-on-year growth, solidifying its leadership in the hematologic oncology field [2] - Sales in the United States reached 8.96 billion yuan, a 51.7% increase, driven by strong demand across all indications and favorable net pricing [2] - European sales amounted to 1.92 billion yuan, up 81.4%, attributed to increased market share in major European markets including Germany, Italy, Spain, France, and the UK [2] - In China, sales were 1.19 billion yuan, a 36.5% increase, due to growth in approved indications [2] Additional Product Insights - Sales of Baizean (Tislelizumab injection) totaled 2.64 billion yuan, reflecting a 20.6% year-on-year increase, driven by new patient demand from newly approved indications included in medical insurance [2] - Baizean has achieved a leading market share in the PD-1 market in China [2]

Core Insights - The company reported a strong performance in Q2 2025, with total revenue reaching $1.3 billion, a 42% year-over-year increase [1] - The global revenue from Baiyueze (Zebutinib) was $950 million, reflecting a 49% growth compared to the previous year [1] - GAAP net profit for Q2 2025 was $94 million, an increase of $215 million from the previous year's loss, driven by revenue growth and operational leverage improvements [1] Financial Performance - Gross margin for global product revenue was 87.4% in Q2 2025, up from 85.0% in the same period last year [1] - Adjusted gross margin (excluding depreciation and amortization) increased to 88.1% in Q2 2025, compared to 85.4% in the prior year [1] - The company expects full-year total revenue guidance for 2025 to be between $5 billion and $5.3 billion, supported by strong growth expectations for Baiyueze in the U.S. and continued expansion in Europe and other key markets [1] Strategic Outlook - The company anticipates over 20 milestone advancements in its hematologic and solid tumor pipelines within the next 18 months [1][2] - Baiyueze is positioned as a best-in-class BTK inhibitor with the broadest range of approved indications, maintaining a leading advantage in the U.S. market due to its efficacy and safety profile [2] - Two additional hematologic products, a BCL2 inhibitor and a BTK chimeric degradation activating compound (CDAC), are in Phase 3 clinical trials and are expected to announce key data and initiate new clinical trials soon [2]

Core Viewpoint - Company BeiGene announced an upward revision of its revenue forecast for 2025, expecting revenue to be between RMB 35.8 billion and RMB 38.1 billion, an increase of RMB 600 million from the previous estimate [1] Revenue and Expenses - The company anticipates total R&D, sales, and management expenses to be between RMB 29.5 billion and RMB 31.9 billion, consistent with prior adjustments [1] - The gross margin is expected to be in the mid-to-high range of 80% to 90%, also revised upward from previous estimates [1] Cash Flow and Profitability - The company expects its annual revenue to exceed the total of its cost of goods sold, sales expenses, management expenses, and R&D expenses [1] - The net cash flow from operating activities, after deducting capital expenditures for fixed asset purchases, is projected to be positive [1]

本公告所载的百济神州有限公司（以下简称"百济神州"或"公司"）2025 年半年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司 2025 年半年度报告中披露的数据为准，提请投资者注意投资风险。 A 股代码：688235 A 股简称：百济神州 公告编号：2025-028 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 2025年半年度主要财务数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 本公告财务数据按中国企业会计准则编制并呈列。 本公司已于 2025 年 8 月 6 日同步发布了根据美国公认会计原则及美国证券交 易委员会适用规则编制的截至 2025 年 6 月 30 日止三个月及六个月未经审计财务业 绩，提请投资者注意与本公告区别。 1 一、2025 年半年度主要财务数据和指标 单位：人民币千元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 17,518,269 ...

A 股代码：688235 A 股简称：百济神州 公告编号：2025-029 港股代码：06160 港股简称：百济神州 | | 调整前 2025 | 年度经营业绩预 | | 调整后 2025 | 年度经营业绩预 | | | --- | --- | --- | --- | --- | --- | --- | | | | 测 | | | 测 | | | 营业收入 | 将介于人民币 | 亿元至 352 | 381 | 将介于人民币 | 358 | 亿元至 381 | | | | 亿元之间 | | | 亿元之间 | | | 研发费用、销售及管理费 | 将介于人民币 | 295 亿元至 | 319 | 将介于人民币 | 295 | 亿元至 319 | | 用合计 | | 亿元之间 | | | 亿元之间 | | 1 | 毛利率 % | 80%至 90%的中位区间 | 80%至 90%的中高位区间 | | --- | --- | --- | | 营业收入扣除营业成本、 研发费用、销售及管理费 | 全年营业收入预计将大于营业 成本、销售费用、管理费用及 | 全年营业收入预计将大于营业 成本、销售费用、管理费用及 | | 用 | ...

百济神州8月6日公告，第二季度总收入达13亿美元，同比增长42%。第二季度，基本和稀释每股收益分 别为0.07美元和0.06美元，基本和稀释每股美国存托股份（ADS）收益分别为0.87美元和0.84美元；上年 同期基本每股亏损为0.09美元，基本每股ADS亏损为1.15美元。 ...